Wyniki wyszukiwania

Szukana fraza: collaboration

13 wyników
  • OncoArendi and Galapagos enter into exclusive collaboration on chitinase inhibitors in fibrosis

    Mechelen, Belgium and Warsaw, Poland, 5 November 2020, 22:15 CET – Galapagos NV (Euronext & NASDAQ: GLPG) and OncoArendi Therapeutics SA (WSE: OAT), announced that they have signed an exclusive collaboration and license agreement for the global development and commercialization of OncoArendi’s OATD-01. OATD-01 is a Phase 2-ready chitotriosidase/acidic mammalian chitinase (CHIT1/AMCase) inhibitor for the […]

    Przejdź do strony
  • OncoArendi Therapeutics broadens its collaboration with VIB, a leading life science research institute in Europe, to investigate the role of chitinase family of proteins as potential therapeutic targets in COVID-19 patients

    OncoArendi Therapeutics SA today signed an agreement with VIB, one of the world leading life science research institutes. The scope of this research collaboration focuses on the role of chitinase and chitinase-like-proteins (CLPs) in COVID-19 and subsequent complication. This collaboration can lead to identification of new drug candidates that can alleviate COVID-19 complications, such as […]

    Przejdź do strony
  • Dr. Zbigniew Zasłona joins OncoArendi Therapeutics as the new Director of the Biology Department. Dr Paweł Dobrzański, the current head of the Biology Department, will still be engaged in collaboration with OncoArendi as Senior Scientific Advisor on the company’s Scientific Advisory Board.

    Dr. Zbigniew Zasłona, a biologist and scientist with impressive achievements in the area of pulmonary diseases (at Trinity College Dublin since 2015) has joined the research team of OncoArendi Therapeutics S.A. Prior to his collaboration with OncoArendi dr. Zasłona was a Senior Investigator at a biopharmaceutical company Sitryx, where he was responsible for studies on […]

    Przejdź do strony
  • OncoArendi Therapeutics Announces a License Option Agreement with University of Michigan

    – Option to in-license and develop small molecule leads against a novel target for the treatment of fibrotic diseases – Strengthens pipeline and reinforces OncoArendi’s strategic focus on fibrotic diseases including idiopathic pulmonary fibrosis (IPF) 11 March  2022 – OncoArendi Therapeutics S.A. (”OncoArendi”; WSE: OAT), a clinical stage biotechnology company that uses its world leading […]

    Przejdź do strony
  • OncoArendi Therapeutics Appoints Dr. Adam Gołębiowski, Dr. Zbigniew Zasłona and Agnieszka Rajczuk-Szczepańska to its Management Board  

    New members to bring additional scientific, operational and HR expertise  Warsaw, Poland – 31 January 2022 – OncoArendi Therapeutics S.A. (”OncoArendi”; WSE: OAT), a clinical stage biotechnology company that uses its world leading medicinal capabilities to discover and develop first in class small molecule drug candidates that directly modulate RNA and unexplored protein targets to […]

    Przejdź do strony
  • OncoArendi Therapeutics Appoints Samson Fung, M.D. as Chief Medical Officer

    Dr. Fung to Lead Global Clinical Development, Translational Science and Regulatory Strategies Warsaw, Poland – 27 January 2022 – OncoArendi Therapeutics S.A. (”OncoArendi”; WSE: OAT), a clinical stage biotechnology company that uses its world leading medicinal capabilities to discover and develop first in class small molecule drug candidates that directly modulate RNA and unexplored protein […]

    Przejdź do strony
  • OncoArendi Therapeutics supervisory board welcomes international biopharmaceutical experts: Nancy Van Osselaer, Paul van der Horst and Rafal Kamiński as its new members

    OncoArendi Therapeutics supervisory board welcomes international biopharmaceutical experts: Nancy Van Osselaer, Paul van der Horst and Rafal Kamiński as its new members Appointments bring global leadership experience and expertise in drug discovery, as well as clinical and business development Warsaw, Poland – 14 January 2022 – OncoArendi Therapeutics S.A. (”OncoArendi”; WSE: OAT), a clinical stage […]

    Przejdź do strony
  • OncoArendi continues to grow by executing further steps of the strategy and initiates two new drug discovery programs within its existing research platforms

    According to the strategy released in March, OncoArendi Therapeutics S.A. (WSE: OAT) expands its existing innovative drug discovery platforms by launching two new programs: CHIT1 SELECTIVE focusing on new therapeutic areas within the chitinase platform and a new program in the deubiquitinase (DUBs) platform in oncology indications. These activities are in line with strategic plans […]

    Przejdź do strony
  • OncoArendi executes the strategy for 2021-2025 in the area of R&D platform for developing small molecules modulating RNA function

    · On June 16 2021, the Company signed a scientific cooperation agreement with the International Institute of Molecular and Cell Biology in Warsaw (IIMCB) in the field of discovery and development of small molecule drugs modulating the function of RNA · OncoArendi also entered exclusive negotiations with IIMCB of a licensing agreement (License Execution Agreement) […]

    Przejdź do strony
  • Drug Candidate OATD-01 may find use in treatment of pulmonary fibrosis in patients who have survived a new coronavirus infection (COVID-19)

    Potential effectiveness of OATD-01 in the treatment of pulmonary fibrosis is based on a unique mechanism of inhibiting a new biological target – chitotriosidase 1 (CHIT1) Linking COVID-19 infection to pulmonary fibrosis where CHIT1 plays a role will increase the value of OATD-01 and other chitinase inhibitors for potential partners

    Przejdź do strony
  • New Head of Research (Chief Scientific Officer) at OncoArendi

    OncoArendi has recently hired dr. Rafał Kamiński for the position of Chief Scientific Officer. He has acquired broad international experience in discovery and development of innovative small molecule drugs and management of scientific teams from previous work for global pharmaceutical companies. Immediately prior to accepting the CSO position at OncoArendi Therapeutics, dr. Kamiński worked for […]

    Przejdź do strony
  • OncoArendi Therapeutics Gets Listed

    [vc_row][vc_column width=”1/1″][vc_column_text] Warsaw, 18 December 2017 Press Release   OncoArendi Therapeutics Gets Listed   OncoArendi Therapeutics S.A., an innovative, clinical stage, biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics for cancer and respiratory diseases, has filed documents with the Financial Supervision Authority, initiating the process aiming for the initial public offering (IPO) of […]

    Przejdź do strony